Lanean...

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase inhibitor, has demonstrated efficacy as monotherapy in trials of myeloid malignancy, and this efficacy appears enhanced in combination with conven...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Haematologica
Egile Nagusiak: Fathi, Amir T., Wander, Seth A., Blonquist, Traci M., Brunner, Andrew M., Amrein, Philip C., Supko, Jeffrey, Hermance, Nicole M., Manning, Amity L., Sadrzadeh, Hossein, Ballen, Karen K., Attar, Eyal C., Graubert, Timothy A., Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y., Som, Tina T., Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Chen, Yi-Bin
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2017
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5395112/
https://ncbi.nlm.nih.gov/pubmed/28034990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.158394
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!